SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Geron Corp.
An SI Board Since November 1996
Posts SubjectMarks Bans Symbol
3576 157 0 GERN
Emcee:  XenaLives Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3351BioTime and BioTime Acquisition Corporation Announce Combined $10 Million FinanSavant-11/15/2012
3350LifeMap Sciences, Inc. Announces Addition to Board of Directors and Provides UpSavant-10/19/2012
3349Geron Board to Review BioTime's Offer to Buy Stem Cell Assets Last Update:Savant-10/19/2012
3348BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation ALAMEDA,Savant-10/18/2012
3347BioTime Proposes Buying Geron's Stem Cell Assets Last Update: 10/18/2012 9Savant-10/18/2012
3346BioTime Forms BioTime Acquisition Corporation Subsidiary will seek to acquire Savant-10/18/2012
3345I bought some GERN today @ $1.53...............BioTime makes offer for Geron stecycleupcycledown-10/18/2012
3344UPDATE: Geron Ends Study of Breast Cancer Drug; Shares Plunge Last Update: 9/1Savant19/11/2012
3343Out of the blue....Geron Ends Study of Imetelstat for Breast Cancer; Cites ShortSavant-9/10/2012
3342Geron Started At Buy By Stifel NicolausSavant-8/30/2012
3341seekingalpha.comSavant-8/17/2012
3340July 3rd.. Geron Corp Registers Mixed-Securities Shelf For Up To $200M Last UpSavant-7/31/2012
3339Geron beats by $0.01, misses on revs Reports Q2 (Jun) loss of $0.14 per share, Savant-7/31/2012
3338Unfortunately, I have to disagree at this point. GERN has become just another bCasaubon-6/30/2012
3337INTRO Here's my semi-annual exercise to see if I remember why I own the stoctktrimbath-6/30/2012
3336Geron beats by $0.03, beats on revs Reports Q1 (Mar) loss of $0.15 per share, $Savant-5/3/2012
3335DePinho and Sahin recently published on the adaptive mechanisms provoked by antiCasaubon14/22/2012
3334My semi-annual review of Geron INTRO Here's my semi-annual exercise to see tktrimbath-12/31/2011
3333Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer Savant112/12/2011
3332Yes, at least. That's quality market research for ya...lol That's also Savant-11/29/2011
3331This research note says the cancer drug market in the US is $30 million. They haFJB-11/29/2011
3330Research from BioMed Tracker and BIO claims that the cancer drug success rate isSavant-11/29/2011
3329Geron to Focus on Its Novel Cancer Programs Company Plans to Partner All Stem Savant-11/15/2011
3328Geron: Phase 2 Trials To Be Initiated In Patients With Brain Metastases Savant-11/15/2011
3327Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC Nov 15Savant-11/15/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News